Historical controls for metastatic pancreatic cancer: Benchmarks for planning and analyzing single-arm phase II trials

Philip A. Philip, Kari Chansky, Michael LeBlanc, Lawrence Rubinstein, Lesley Seymour, S. Percy Ivy, Steven Robert Alberts, Paul J. Catalano, John Crowley

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

We compiled and analyzed a database of cooperative group trials in advanced pancreatic cancer to develop historical benchmarks for overall survival (OS) and progression-free survival (PFS). Such benchmarks are essential for evaluating new therapies in a single-arm setting. The analysis included patients with untreated metastatic pancreatic cancer receiving regimens that included gemcitabine, between 1995 and 2005. Prognostic baseline factors were selected by their significance in Cox regression analysis. Outlier trial arms were identified by comparing individual 6-month OS and PFS rates against the entire group. The dataset selected for the generation of OS and PFS benchmarks was then tested for intertrial arm variability using a logistic-normal model with the selected baseline prognostic factors as fixed effects and the individual trial arm as a random effect. A total of 1,132 cases from eight trials qualified. Performance status and sex were independently significant for OS, and performance status was prognostic for PFS. Outcomes for one trial (NCCTG-034A) were significantly different from the other trial arms. When this trial was excluded, the remaining trial arms were homogeneous for OS and PFS outcomes after adjusting for performance status and sex. Benchmark values for 6-month OS and PFS are reported along with a method for using these values in future study design and analysis. The benchmark survival values were generated from a dataset that was homogeneous between trials. The benchmarks can be used to enable single-arm phase II trials using a gemcitabine platform, especially under certain circumstances. Such circumstances might be when a randomized control arm is not practically feasible, an early signal of activity of an experimental agent is being explored such as in expansion cohorts of phase I studies, and in patients who are not candidates for combination cytotoxic therapy.

Original languageEnglish (US)
Pages (from-to)4176-4185
Number of pages10
JournalClinical Cancer Research
Volume20
Issue number16
DOIs
StatePublished - Aug 15 2014

Fingerprint

Benchmarking
Pancreatic Neoplasms
Disease-Free Survival
gemcitabine
Survival
Survival Rate
Logistic Models
Regression Analysis
Databases
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Philip, P. A., Chansky, K., LeBlanc, M., Rubinstein, L., Seymour, L., Ivy, S. P., ... Crowley, J. (2014). Historical controls for metastatic pancreatic cancer: Benchmarks for planning and analyzing single-arm phase II trials. Clinical Cancer Research, 20(16), 4176-4185. https://doi.org/10.1158/1078-0432.CCR-13-2024

Historical controls for metastatic pancreatic cancer : Benchmarks for planning and analyzing single-arm phase II trials. / Philip, Philip A.; Chansky, Kari; LeBlanc, Michael; Rubinstein, Lawrence; Seymour, Lesley; Ivy, S. Percy; Alberts, Steven Robert; Catalano, Paul J.; Crowley, John.

In: Clinical Cancer Research, Vol. 20, No. 16, 15.08.2014, p. 4176-4185.

Research output: Contribution to journalArticle

Philip, PA, Chansky, K, LeBlanc, M, Rubinstein, L, Seymour, L, Ivy, SP, Alberts, SR, Catalano, PJ & Crowley, J 2014, 'Historical controls for metastatic pancreatic cancer: Benchmarks for planning and analyzing single-arm phase II trials', Clinical Cancer Research, vol. 20, no. 16, pp. 4176-4185. https://doi.org/10.1158/1078-0432.CCR-13-2024
Philip, Philip A. ; Chansky, Kari ; LeBlanc, Michael ; Rubinstein, Lawrence ; Seymour, Lesley ; Ivy, S. Percy ; Alberts, Steven Robert ; Catalano, Paul J. ; Crowley, John. / Historical controls for metastatic pancreatic cancer : Benchmarks for planning and analyzing single-arm phase II trials. In: Clinical Cancer Research. 2014 ; Vol. 20, No. 16. pp. 4176-4185.
@article{5d858ac6f4c34a2a9f0f49b9c0c45c30,
title = "Historical controls for metastatic pancreatic cancer: Benchmarks for planning and analyzing single-arm phase II trials",
abstract = "We compiled and analyzed a database of cooperative group trials in advanced pancreatic cancer to develop historical benchmarks for overall survival (OS) and progression-free survival (PFS). Such benchmarks are essential for evaluating new therapies in a single-arm setting. The analysis included patients with untreated metastatic pancreatic cancer receiving regimens that included gemcitabine, between 1995 and 2005. Prognostic baseline factors were selected by their significance in Cox regression analysis. Outlier trial arms were identified by comparing individual 6-month OS and PFS rates against the entire group. The dataset selected for the generation of OS and PFS benchmarks was then tested for intertrial arm variability using a logistic-normal model with the selected baseline prognostic factors as fixed effects and the individual trial arm as a random effect. A total of 1,132 cases from eight trials qualified. Performance status and sex were independently significant for OS, and performance status was prognostic for PFS. Outcomes for one trial (NCCTG-034A) were significantly different from the other trial arms. When this trial was excluded, the remaining trial arms were homogeneous for OS and PFS outcomes after adjusting for performance status and sex. Benchmark values for 6-month OS and PFS are reported along with a method for using these values in future study design and analysis. The benchmark survival values were generated from a dataset that was homogeneous between trials. The benchmarks can be used to enable single-arm phase II trials using a gemcitabine platform, especially under certain circumstances. Such circumstances might be when a randomized control arm is not practically feasible, an early signal of activity of an experimental agent is being explored such as in expansion cohorts of phase I studies, and in patients who are not candidates for combination cytotoxic therapy.",
author = "Philip, {Philip A.} and Kari Chansky and Michael LeBlanc and Lawrence Rubinstein and Lesley Seymour and Ivy, {S. Percy} and Alberts, {Steven Robert} and Catalano, {Paul J.} and John Crowley",
year = "2014",
month = "8",
day = "15",
doi = "10.1158/1078-0432.CCR-13-2024",
language = "English (US)",
volume = "20",
pages = "4176--4185",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "16",

}

TY - JOUR

T1 - Historical controls for metastatic pancreatic cancer

T2 - Benchmarks for planning and analyzing single-arm phase II trials

AU - Philip, Philip A.

AU - Chansky, Kari

AU - LeBlanc, Michael

AU - Rubinstein, Lawrence

AU - Seymour, Lesley

AU - Ivy, S. Percy

AU - Alberts, Steven Robert

AU - Catalano, Paul J.

AU - Crowley, John

PY - 2014/8/15

Y1 - 2014/8/15

N2 - We compiled and analyzed a database of cooperative group trials in advanced pancreatic cancer to develop historical benchmarks for overall survival (OS) and progression-free survival (PFS). Such benchmarks are essential for evaluating new therapies in a single-arm setting. The analysis included patients with untreated metastatic pancreatic cancer receiving regimens that included gemcitabine, between 1995 and 2005. Prognostic baseline factors were selected by their significance in Cox regression analysis. Outlier trial arms were identified by comparing individual 6-month OS and PFS rates against the entire group. The dataset selected for the generation of OS and PFS benchmarks was then tested for intertrial arm variability using a logistic-normal model with the selected baseline prognostic factors as fixed effects and the individual trial arm as a random effect. A total of 1,132 cases from eight trials qualified. Performance status and sex were independently significant for OS, and performance status was prognostic for PFS. Outcomes for one trial (NCCTG-034A) were significantly different from the other trial arms. When this trial was excluded, the remaining trial arms were homogeneous for OS and PFS outcomes after adjusting for performance status and sex. Benchmark values for 6-month OS and PFS are reported along with a method for using these values in future study design and analysis. The benchmark survival values were generated from a dataset that was homogeneous between trials. The benchmarks can be used to enable single-arm phase II trials using a gemcitabine platform, especially under certain circumstances. Such circumstances might be when a randomized control arm is not practically feasible, an early signal of activity of an experimental agent is being explored such as in expansion cohorts of phase I studies, and in patients who are not candidates for combination cytotoxic therapy.

AB - We compiled and analyzed a database of cooperative group trials in advanced pancreatic cancer to develop historical benchmarks for overall survival (OS) and progression-free survival (PFS). Such benchmarks are essential for evaluating new therapies in a single-arm setting. The analysis included patients with untreated metastatic pancreatic cancer receiving regimens that included gemcitabine, between 1995 and 2005. Prognostic baseline factors were selected by their significance in Cox regression analysis. Outlier trial arms were identified by comparing individual 6-month OS and PFS rates against the entire group. The dataset selected for the generation of OS and PFS benchmarks was then tested for intertrial arm variability using a logistic-normal model with the selected baseline prognostic factors as fixed effects and the individual trial arm as a random effect. A total of 1,132 cases from eight trials qualified. Performance status and sex were independently significant for OS, and performance status was prognostic for PFS. Outcomes for one trial (NCCTG-034A) were significantly different from the other trial arms. When this trial was excluded, the remaining trial arms were homogeneous for OS and PFS outcomes after adjusting for performance status and sex. Benchmark values for 6-month OS and PFS are reported along with a method for using these values in future study design and analysis. The benchmark survival values were generated from a dataset that was homogeneous between trials. The benchmarks can be used to enable single-arm phase II trials using a gemcitabine platform, especially under certain circumstances. Such circumstances might be when a randomized control arm is not practically feasible, an early signal of activity of an experimental agent is being explored such as in expansion cohorts of phase I studies, and in patients who are not candidates for combination cytotoxic therapy.

UR - http://www.scopus.com/inward/record.url?scp=84905981785&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84905981785&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-13-2024

DO - 10.1158/1078-0432.CCR-13-2024

M3 - Article

C2 - 24914040

AN - SCOPUS:84905981785

VL - 20

SP - 4176

EP - 4185

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 16

ER -